Dataset from A Phase 3, Open-label, Single-Arm Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 3 Doses of 13vPnC Vaccine in HIV-Infected Subjects 18 Years of Age or Older Who Have Been Previously Immunized With 23vPS Vaccine
收藏NIAID Data Ecosystem2026-05-02 收录
下载链接：
https://doi.org/10.25934/00006768
下载链接
链接失效反馈官方服务：
资源简介：
The study will evaluate the safety, tolerability and immunogenicity of a 13-valent
pneumococcal conjugate vaccine (13vPnC) in HIV-infected subjects 18 years of age or older who
have been previously immunized with at least one dose of 23-valent pneumococcal
polysaccharide vaccine (23vPS). All subjects will receive 3 doses of 13vPnC, with each study
vaccine dose given approximately 6 months apart.
创建时间：
2024-11-27
